Cytokinetics Names Robert E. Landry to Board of Directors

Core Insights - Cytokinetics has appointed Robert E. Landry to its Board of Directors, enhancing the company's financial and operational expertise as it approaches potential commercialization of its first medicine [2][3] - Landry has over 30 years of experience in the pharmaceutical industry, including 11 years as CFO at Regeneron Pharmaceuticals, where he played a key role in the company's growth and acquisitions [2][3][4] - The company is preparing for the potential approval and launch of aficamten, a cardiac myosin inhibitor, following positive results from the SEQUOIA-HCM Phase 3 clinical trial [5] Company Overview - Cytokinetics is a late-stage biopharmaceutical company focused on muscle biology and developing treatments for diseases that compromise muscle performance [5] - The company is also developing other drug candidates, including omecamtiv mecarbil for heart failure and CK-586 for heart failure with preserved ejection fraction [5] Leadership and Expertise - Robert I. Blum, President and CEO of Cytokinetics, emphasized the importance of Landry's financial expertise in guiding the company towards sustainable growth and commercialization [3] - Landry's previous experience includes significant roles at Wyeth and Pfizer, where he held various corporate and operational positions [4]